ArticleFrontiers in pharmacology2025

Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system.

Lingti Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.